Emmaus Life Sciences Inc (OTCQX:EMMA) announced that the Kuwaiti Ministry of Health has granted marketing authorization for the commercial distribution and sale of its Endari product in the Gulf country.
The Torrance, California-based firm said it has received Registration Approval from the Pharmaceutical and Herbal Medicines Registration and Control Administration (Drug and Food Control) of the Kuwaiti Ministry of Health, making Kuwait the latest Gulf Cooperation Council country to grant full marketing approval for Endari following approvals in the United Arab Emirates and the State of Qatar earlier this year.
In addition to the US, Endari is available on an early access basis in Bahrain and the Kingdom of Saudi Arabia pending official notice of action on Emmaus's marketing authorization applications in those countries.
READ: Emmaus Life Sciences receives first major purchase order in Saudi Arabia
Endari reduces acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Emmaus CEO Dr Yutaka Niihara told investors that the firm is progressing its mission to make Endari available to the many sickle cell patients in the Gulf countries.
"We are hopeful that sales in the region and increased domestic sales will help us to generate positive operating cash flows beginning in 2023,” the CEO said in a statement.
George Sekulich, senior vice president of global commercialization of Emmaus, added: "Receiving the approval to market Endari in Kuwait is another critical step forward for Emmaus, patients in the region, and clinicians. We look ahead to expanding our presence in this market and continuing working with our trusted partners."
Emmaus is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas